Mojave Brands Inc.

Investor Presentation

(to be renamed Light AI Inc.)



Detecting Infectious Diseases Instantly

Applying Artificial Intelligence (“AI”) to smartphone images to identify disease in seconds – a patented, app-based solution.

October 29 2024

A preliminary prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in each of the provinces and territories of Canada, other than Quebec, and is accessible through SEDAR+. Copies of the preliminary prospectus and any amendment may be obtained from Ventum Financial Corp. by email at ecm@ventumfinancial.com. The preliminary prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued. This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the preliminary prospectus, the final prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered before making an investment decision.

Disclaimer

Forward-Looking Statement

This presentation contains forward-looking statements with respect to Mojave Brands Inc. (the "**Company**") and Light AI Inc. ("**Light AI**"). By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, the forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that the Company's assumptions may not be correct and that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as "anticipate", "will", "expect", "may", "continue", "could", "estimate", "forecast", "plan", "potential" and similar expressions.

Forward-looking statements contained in this presentation and other forward-looking statements are based on management of the Company's and Light AI's opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Forward-looking statements contained in this presentation may include, but are not limited to statements with respect to:

- the completion of the acquisition of Light AI by the Company pursuant to the Business Combination Agreement dated June 19, 2024, as amended, among the Company, Light AI and LAI SPV Corp. (the "**Transaction**") and the listing of the Company's common shares on CBOE Canada
- the intention for the Company to change its name to "Light AI Inc." upon completion of the Transaction (such entity will be referred as the "**Resulting Issuer**");
- the timing and closing of the offering;
- the satisfaction of the conditions to closing of the offering, including the receipt, in a timely manner, of regulatory and other required approvals;
- the terms of the offering (including the manner of distribution);
- the anticipated use of the net proceeds of the offering;
- the intentions, plans and future actions of the Resulting Issuer;
- the business and future activities of the Resulting Issuer and anticipated developments in the operations of the Resulting Issuer;
- the business objectives for the next 12 months of the Resulting Issuer;
- the anticipated cash and additional financing needs of the Resulting Issuer;
- the performance of the Resulting Issuer's business and operations;
- the length of time required to obtain permits, certifications and approvals;
- the Resulting Issuer's expected reliance on key management personnel, advisors and consultants;
- expectations regarding trends in the healthcare industry;
- results and expectation concerning various partnerships, strategic alliances, projects and marketing strategies of the Resulting Issuer; and
- the economy generally.

Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Readers are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements based on certain risk factors, which include, but not limited to:

- the ability to complete the Transaction;
- the ability to achieve the desired synergies and benefits of the Transaction;
- the completion of the offering is subject to conditions;
- the market price for the Common Shares may be volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond the Resulting Issuer's control;
- Light AI has limited operating history, which makes it difficult to evaluate the Resulting Issuer's business prospects;
- the Resulting Issuer's financial position and results of operations may differ materially from expectations;
- the proposed management of the Resulting Issuer has limited experience managing a publicly-traded company;
- the Resulting Issuer expects to incur future losses and may never generate revenues;
- the Resulting Issuer may be unable to generate revenues or establish a subscription-based revenue model;
- the Resulting issuer expects to require additional capital to support its business;
- the Resulting Issuer may never achieve profitability;
- the Resulting Issuer's dependent on senior management team and key employees;
- the Resulting Issuer's market opportunity and cost saving estimates are subject to significant uncertainty which may prove to be inaccurate;
- the Resulting Issuer may face growth-related risks;
- the Resulting Issuer could incur material losses relating to cyber-attacks or other information security breaches in the future;
- the risks associated with operating in a complex healthcare and technology regulatory and legal environment subject to a wide variety of laws and regulations, including those relating to provision of healthcare, consumer products, product liability and consumer protection; those relating to negligence; those relating to the manner in which the Resulting Issuer advertises, markets and sells products and services; labour and employment laws, including wage and hour laws; tax laws or interpretations thereof; data protection and privacy laws and regulations;
- the Resulting Issuer may face competition in its industry;
- the Resulting Issuer may be unable to adequately protect its proprietary and intellectual property rights;
- the Resulting Issuer's reliance on obtaining and maintain regulatory approval in jurisdictions where its products or technologies are being researched, developed or commercialized;
- unfavorable global economic and political conditions could adversely affect the Resulting Issuer's business, financial condition or results of operations;
- the Resulting Issuer may vary from its disclosed intended use of proceeds;
- an investment in the Resulting Issuer's securities may have income tax consequences.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking statements contained in this presentation or in certain of the other documents on file with Canadian securities regulatory authorities, which are available on the Company's SEDAR+ profile at www.sedarplus.ca. The Company and its directors, officers and employees each disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable law. Accordingly, readers should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Disclaimer

Market & Industry Data

This presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company and Light AI believe these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company and Light AI have not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

Trademarks

This presentation includes certain trademarks that are protected under applicable intellectual property laws and are the property of Light AI. Solely for convenience, these trademarks may appear without the ® or ™ symbol, but such references are not intended to indicate, in anyway, that Light AI will not assert its rights to these trademarks to the fullest extent under applicable law. This presentation also contains trademarks of third parties which are the property of their respective owners. The use or display of these third parties' trademarks is not intended to, and does not imply, a relationship with the Company or Light AI, or an endorsement or sponsorship by or of the Company or Light AI.

U.S. Securities Law

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of the Company or Light AI in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold within the United States, unless an exemption from such registration is available, information concerning the assets and operations of the Company or Light AI included in this presentation has been prepared in accordance with Canadian standards and is not comparable in all respects to similar information for United States companies.

No securities regulatory authority has expressed an opinion about these securities and it is an offense to claim otherwise.

An investment in the Company's securities should be considered highly speculative, and involves a high degree of risk that should be considered by potential investors. There is no guarantee that an investment in the Company will earn any positive return in the short or long term. An investment in the Company is appropriate only for investors who are wiling to risk a loss of all of their investment and who can afford to lose all of their investment. There are certain risk factors associated with an investment in the Company's securities and these risk factors should be reviewed carefully and evaluated by readers. Investors should read the preliminary prospectus, the final prospectus and any amendment and consider the material facts and risk factors in connection with an investment in any of the Company's securities.

Transaction Overview

PROPOSED TRANSACTION

Mojave Brands Inc. (“Mojave”, the “Company”) (CSE: MOJO) to combine with Light AI Inc. (“Light AI”), a BC private company and LAI SPV Corp. (“LAI SPV”), a BC private company incorporated for the purposes of completing the business combination (the “Transaction”).

FORMER SECURITY HOLDERS	SHARE EXCHANGE	
Mojave securities	→ **1 old: 1 new basis**	**Combined entity securities**
Light AI securities	→ **1 old:3.89 new basis**	**Combined entity securities**
LAI SPV securities	→ **1 old: 1 new basis**	**Combined entity securities**

Following the Transaction, the Company intends to list its Common Shares on CBOE Canada and change its name to “Light AI Inc.”

LightAI is Addressing Two of the Most Pressing Public Health Issues of our Time

[1] Antimicrobial resistance from over-prescription and misuse of antibiotics is consistently listed as a top 5 global health threat[1]

WHO Names Top 10 Global Threats

[2] Strep A infects more than 600M people globally every year, killing as many children as malaria[2]

"Strep A sore throat can also result in post-infection sequelae including acute post-streptococcal glomerulonephritis, acute rheumatic fever (ARF), and rheumatic heart disease (RHO)…Strep A was postulated to be the fifth most lethal pathogen in the world."[3]

"Antibiotic resistance is one of the biggest threats to global health, food security, and development"[4]

World Health Organization

In the United States, for every 10 sore throats treated by a physician, there are 6 antibiotic prescriptions written, yet only 2 or 3 are bacterial infections.

Confidential - Property of Light AI, Inc.

Light AI Highlights

AI Platform	Paradigm shift: Light AI has patented an AI platform to detect infectious diseases by analyzing smartphone images in seconds. Initial target Strep A. Proprietary cloud-based library of 300,000 images.
Capital, Time, Partners	LightAI and LAI SPV have raised over $18M (not including SRED), and it has taken 8 years and 13 partners to get Light AI where it is today.
AI Veterans and Healthcare Luminaries	From organizations such as Johnson & Johnson, Medtronic, Bristol Meyers Squibb, the CDC and WHO. Peter Whitehead, Light AI's founder and CEO, is the inventor of the VELScope. The VELScope has been used in over 50M oral health examinations by over 10,000 dental practitioners in 23 countries.
Commercial Ready	Multiple Go-To-Market paths, including the joint venture with TC4A to launch in lower middle income countries.
Simple to Use	The user opens an app on a smartphone and follows basic instructions that include accessing the camera. The process takes ~45 seconds and ~10 seconds to analyze the image in the cloud.
Hyper Scale Growth Potential	No swabs, labs or proprietary hardware required— just a smartphone. Leveraging massive global smartphone footprint to manage a global infectious disease problem.

Massive infectious footprint + Instant screening results = Hyper scale growth opportunity

Confidential - Property of Light AI, Inc.

An Iteratively Improving AI Model (Multiple Validation Studies)



Proposed Nominees for Directors, Officers and Advisors

Proposed Management post RTO

Peter Whitehead
CEO & Founder

- 24 years experience in healthcare innovation
- Inventor of VELScope, a market leading oral cancer imaging tool
- Founder of multiple AI/Machine Learning companies & patents

Thomas Scarnecchia,
COO

- 30 years as a technology executive & consultant
- Former CIO and VP, Johnson & Johnson R&D
- Expertise in building data science and computational science teams

Darren Tindale
CFO

- Over 20 years of financial accounting, corporate secretarial and regulatory compliance services.
- CFO and Corporate Secretary to a diverse range of both private and public companies listed on the TSXV and the CSE.

Proposed Board Members post RTO

Steve Semmelmayer
Chairman of the Board

- 37 year veteran of the Dental Industry
- Former CEO, Denmat Holdings & Discus Dental
- Former CEO, LED Medical Diagnostics

Peter Whitehead
CEO & Founder

- 24 years experience in healthcare innovation
- Inventor of VELScope, a market leading oral cancer imaging tool
- Founder of multiple AI/Machine Learning companies & patents

Mark Attanasio
Board Nominee

- CEO ATTA Elevators Corp. & Owner of Nocera Investment Corp.
- Specialist in Canadian Venture Capital
- Former CEO Eight Capital & Dundee Capital Markets

Emmanuel Blin
Board Nominee

- CEO & Founder TC4A, a global digital healthcare platform
- Former Chief Strategy Officer Bristol Myers Squibb

Hugh Cleland
Board Nominee

- Co-founder & Portfolio Manager of Roadmap Capital
- BA from Harvard University, CFA Designation (2001)
- Awarded the "Opportunities Strategy Hedge Fund Award" for the Northern Rivers Innovation Fund in 2006.

Proposed Advisory Committee post RTO

Yu Zhao (Advisor)

- President of Bridging Consulting LLC, a boutique regulatory firm dedicated to servicing AI startups and medical device companies.
- 16 years at Medtronic, including as Director and Interim VP of Regulatory Affairs

Raymond Ng (Advisor)

- University of British Columbia, Director of Data Science Institute
- Ph.D, Computer Science ML Leader

David Bell (Advisor)

- Public health and internal physician, previously coordinated malaria diagnostics at WHO
- Programme Head of Malaria & Acute Febrile Disease at Foundation for Innovative New Diagnostics

David Talan (Advisor)

- UCLA Emergency Department MD, Infectious Disease
- Principle investigator for the CDC's national sentinel network in the United States (EMERGnEcy ID NET)

Problem

Current Medical Diagnostics System

24-72+ Hours

Doctor Visit
Patient examination with a referral to lab for further testing

Lab Test
Patient's specimen sent to lab for processing

Lab Results
Additional time required to test and return results to doctor

Follow-Up Visit
Another appointment is scheduled to review lab results with the patient

Treatment Plan
Appropriate treatment can commence, which may include prescribed medications

Light AI

Immediate
(on demand)

<u>Antibiotic Misuse</u> 10/10 have indication 6/10 receive antibiotics

ONLY 2 or 3 out of 10 need antibiotics[5,6]

Confidential - Property of Light AI, Inc.

How It Works | Identifies Infection within Seconds



Contact HCP*

Patient and healthcare provider meet in person or over a telemedicine session. Symptoms are captured.



Scan Session Initiated

The patient is prompted to scan their throat. Light AI technology automatically identifies biomarkers to analyze.



Scan Analysis

Light AI immediately analyzes the scan data and returns results within seconds.

On-Demand

Decision support that is immediately accessible, real time, inexpensive, non-invasive, pain free and accurate.

*Health Care Provider

Strep A | Light AI Addresses Major Unmet Needs

Need for Urgency	Strep requires timely test results due to the potential health implications and the urgent need for treatment.
Costly Infrastructure	Common tests like a throat swab require testing capabilities which are expensive and limited in many countries.
Low POC Accuracy	A doctor cannot accurately identify Strep through a visual assessment unlike other conditions such as skin lesions.
Patient Inconvenience	With only two or three out of ten tests showing a bacterial infection, most doctor visits are unnecessary, and could be avoided with digital screening.
High Patient Volume	Very few conditions have the global reach of Strep, with Group A Strep infecting more than 600 million people globally.

Confidential - Property of Light AI, Inc.

Go-To-Market Paths | LMIC

- **LMIC* distribution partner is TC4A (Tech Care For All).**
- **TC4A is a digital health platform with 120,000 healthcare practitioners in >20 countries.**
- **TC4A CEO and Founder, Emmanuel Blin, is a proposed nominee for the post-transaction board. Mr. Blin is the former Chief Strategy Officer of Bristol Myers Squibb.**
- **Initial focus on Kenya and Uganda healthcare providers.**
- **Based on results, roll out to other LMIC markets.**

*LMIC (Lower Middle Income Countries)

Screening Product

Development Objectives:

- *Develop Android App in addition to existing iOS App*
- *Demonstrate functionality for pilot programs*
- *Design and implementation of prototype*

Regulatory Requirements:

- *Expand and complete clinical studies in Kenya, Uganda, Nigeria and South America*
- *Registration, implementation and commercialization in Kenya, Uganda, Nigeria and South America*

Commercialization Path:

- *Conduct feasibility pilot/study in Kenya*
- *Expand to 16 countries*

Existing Partnerships

Tech Care for All

Go-To-Market Paths | Wellness (DTC)

- **Wellness (DTC) is expected to be Light AI's largest market.**
- **Leverage large distribution ecosystems such as major smartphone manufacturers, pharmacy chains and technology platforms.**
- **No FDA approvals required.**
- **Creating pilot programs.**

Wellness Product

Development Objectives:

- *Modify existing app for the wellness market*

Regulatory Requirements:

- *None*

Commercialization Path:

- *Complete wellness market research*
- *Identify appropriate commercial partners*

Confidential - Property of Light AI, Inc.

Go-To-Market Paths | FDA Commercialization Plan

Clear FDA Pathway

- **De Novo Application**
- **New device category: SaMD (Software as a Medical Device)**
- **AI/ML-powered POC (Point-of-care) diagnostic software for rapid detection of Group A Strep**
- **Pre-submission meetings with FDA have taken place to obtain formal guidance on regulatory pathway and clinical study protocol.**

Clinical Trial

- **Single pivotal clinical trial**
- **Strong Clinical Dev Partner**
  - Carelon Research (Elevance Health)

Launch Plan

- **Reimbursement Available**
  - Expected to be available subject to FDA approval
- **Distribution Channel**
  - B2B to HCPs
- **Discussions with global distribution partners**

Anticipated Timeline

LMIC WELLNESS FDA



*The timing associated with obtaining FDA approval depends heavily on the outcome of the prior clinical studies of the Company and feedback from the FDA, as applicable. The anticipated timeline provided herein is inherently speculative, subject to uncertainty and based on the Company's estimates only. Actual timing may vary materially from the disclosure provided herein.

Confidential - Property of Light AI, Inc.

Light AI Granted & Allowed Patents

Grant Date: Jun 2022

Patent 1

https://patents.google.com/patent/US11369318B2/en?inventor=Sarbjit+SARKARIA

Image processing of streptococcal infection in pharyngitis subjects

US11369318B2
United States

Grant Date: Mar 2023

Patent 2

https://patents.google.com/patent/US11602312B2/en?inventor=Sarbjit+SARKARIA

Image processing of streptococcal infection in pharyngitis subjects

US11602312B2
United States

Intention to Grant: May 2024

Patent 3

European Patent

Image processing of streptococcal infection in pharyngitis subjects

EU19871128.5
European Union

Allowance Date: Aug 2024

Patent 4

United States of America

Infection Detection Using Image Data Analysis

35100-48364/US
United States

In addition, 1 patent granted in Australia and 4 other patents pending (2 in Canada, 1 in Europe, 1 in Israel)

Light AI's patents can be broadly characterized as having patented a method to diagnose disease that uses AI algorithms to process images obtained with cameras (including smartphones).

Specific claims about StrepA have also been granted.

Confidential - Property of Light AI, Inc.

Use of Proceeds

	Min Raise	Max Raise
Development of mobile app technology	$4,045,000	$4,045,000
Launch of mobile app technology in lower middle income countries	$1,147,500	$1,620,000
Commercial wellness mobile application pilot studies	$68,000	$400,000
FDA Trials with Carelon Health	$100,000	$100,000
Investor Relations and Marketing	$2,265,000	$3,015,000
General and Administrative Costs for 12 months after completion of the Transaction	$2,712,368	$2,712,368
Transaction Costs	$350,000	$350,000
Unallocated working capital	$357,332	$3,452,832
	$11,045,200	**$15,695,200**

Confidential - Property of Light AI, Inc.

CAP TABLE | Current Offering Details

Mojave Brands Inc.

(to be renamed “Light AI Inc.” upon closing RTO)

Amalgamated Pro Forma Capitalization Table

Share-Exchange	Common Shares	Options	Warrants	Fully Diluted
Light AI Inc.	30,962,069	5,058,945	916,095	36,937,109
Mojave Brands Inc.	9,360,414	-	4,837,400	14,197,814
LAI SPV Corp.	23,756,512	2,055,000	2,039,140	27,850,652
	64,078,995	7,113,945	7,792,635	78,985,575
Convertible Debentures Conversion				
LAI SPV Corp. ($4,054,000 @ $0.25)	16,216,000	-	-	16,216,000
Light AI Inc. ($532,248*)	2,300,495	-	-	2,300,495
Pro Forma Capitalization, Pre RTO Financing**	82,595,490	7,113,945	7,792,635	97,502,070
RTO Financing (Assume Max Raise & no over-allotment option)	27,272,727	-	13,636,363	40,909,090
RTO Financing (Agent Warrants)	-	-	1,909,090	1,909,090
Pro Forma Capitalization, Post RTO Financing***	**109,868,217**	**7,113,945**	**23,338,088**	**140,320,250**

Notes:
*Light AI Convertible Debentures (2023) are priced at $0.90 and convertible on a 3.89:1 basis at closing.
**Assuming completion of maximum offering of $15M (Each Unit shall be comprised of one common share in the capital of the Company and one-half of one common share purchase warrant. Each whole common share purchase warrant is exercisable into an additional common share at a price of $0.80 for a period of 18 months) and assuming no president’s list purchasers.
***subject to rounding

SUMMARY

AI Platform	Paradigm shift: Light AI has patented an AI platform to detect infectious diseases by analyzing smartphone images in seconds. Initial target Strep A. Proprietary cloud-based library of 300,000 images.
Capital, Time, Partners	LightAI and LAI SPV have raised over $18M (not including SRED), and it has taken 8 years and 13 partners to get Light AI where it is today.
AI Veterans and Healthcare Luminaries	From organizations such as Johnson & Johnson, Medtronic, Bristol Meyers Squib, the CDC and WHO. Peter Whitehead, Light AI's founder and CEO, and inventor of the VELScope. The VELScope has been used in over 50M oral health examinations by over 10,000 dental practitioners in 23 countries.
Commercial Ready	Multiple Go To Market paths, including the joint venture with TC4A to launch in lower middle income countries.
Simple to Use	The user opens an app on a smartphone and follows basic instructions that include accessing the camera. The process takes ~45 seconds and ~10 seconds to analyze the image in the cloud.
Hyper Scale Growth Potential	No swabs, labs or proprietary hardware required — just a smartphone. Leveraging massive global smartphone footprint to manage a global infectious disease problem.

Massive infectious footprint + Instant screening results = Hyper scale growth opportunity

Mojave Brands Inc.

(to be renamed Light AI Inc.)

Thank You

Bobby Dubeau, CEO Mojave Brands, bobbydubeau@yahoo.ca
Peter Whitehead, CEO & Founder Light AI, pwhitehead@light.ai
Sheldon Chang, sheldon@commoditypartners.ca
Commodity Partners 604-687-7130

References

1 - *Ten threats to global health in 2019*. World Health Organization. www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019.

2 - Torotice D., Ferranna M., Bloom D. (2023). Optimal global spending for group A Streptococcus vaccine research and development. *npj Vaccines* 8(1), 62. https://doi.org/10.1038/s41541-023-00646-6.

3 - Miller, K. M., Carapetis, J. R., Van Beneden, C. A., Cadarette, D., Daw, J. N., Moore, H. C., Bloom, D. E., & Cannon, J. W. (2022). The global burden of sore throat and group A Streptococcus pharyngitis: A systematic review and meta-analysis. EClinicalMedicine, 48, 101458.

4 - *Fact sheet: Antimicrobial resistance*. World Health Organization. who.int/news-room/fact-sheets/detail/antimicrobial-resistance.

5 - Shulman, S. T., Bisno, A. L., Clegg, H. W., Gerber, M. A., Kaplan, E. L., Lee, G., Martin, J. M., & Van Beneden, C. (2012). Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, *55*(10), 1279–1282. https://doi.org/10.1093/cid/cis847.

6 - Barnett, M. L., & Linder, J. A. (2014). Antibiotic prescribing to adults with sore throat in the United States, 1997-2010. *JAMA internal medicine*, *174*(1), 138–140. https://doi.org/10.1001/jamainternmed.2013.11673.

Confidential - Property of Light AI, Inc.